TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31199860

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 4189

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 4189
Study: 31200009

Group type: EXPERIMENTAL
Intervention: Presence of an anaesthetic nurse and experienced anaesthesiologist
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Anaesthesiologist's experience <15 years and absence of anaesthetic nurse
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Overall complications
Number of subjects: 3535
Study: 31200729

Group type: EXPERIMENTAL
Intervention: Facilitation phase included one session of sub-motor threshold, sensory electrical stimulation followed by neuromuscular electrical stimulation paired with ear movement feedback for up to 8 additional sessions.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Skill acquisition phase using an auricular control device that used sEMG signals to control movements of a cursor through three levels of computer games.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Facilitation and skill phases of training.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Facilitation phase training.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall training protocol.
Number of subjects: 10
Study: 31201031

Group type: EXPERIMENTAL
Intervention: Youth with Down syndrome
Number of subjects: 226

Group type: COMPARATOR
Intervention: Controls (youth without Down syndrome)
Number of subjects: 226
Study: 31201085

Group type: EXPERIMENTAL
Intervention: De-escalation of TKI treatment to half the standard dose for 12 months, then stopped for a further 24 months.
Number of subjects: 174
Study: 31201169

Group type: EXPERIMENTAL
Intervention: Daratumumab (DARA) 16 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib (1.3-1.5 mg/m2)
Number of subjects: 0
Study: 31201186

Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implant (ABI)
Number of subjects: 10
Study: 31201592

Group type: EXPERIMENTAL
Intervention: RV pacing (RVP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: LBBB
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RVP
Number of subjects: 14
Study: 31202287

Group type: EXPERIMENTAL
Intervention: Community Supervision (CS) agencies in rural areas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community Supervision (CS) agencies in urban areas
Number of subjects: 0
Study: 31202757

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31202772

Group type: EXPERIMENTAL
Intervention: Low tube potentials (≤80 kVp)
Number of subjects: 4006

Group type: EXPERIMENTAL
Intervention: Low tube potentials (90 to 100 kVp)
Number of subjects: 4006

Group type: EXPERIMENTAL
Intervention: Low tube potentials
Number of subjects: 4006

Group type: COMPARATOR
Intervention: Conventional tube potentials
Number of subjects: 4006

Group type: COMPARATOR
Intervention: CCTA with 90 to 100 kVp
Number of subjects: 4006
Study: 31203228

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2578
Study: 31203237

Group type: EXPERIMENTAL
Intervention: Dementia-specific respite care concept (DESKK) including mobility training for PwD and counselling for FCs
Number of subjects: 0
Study: 31203390

Group type: EXPERIMENTAL
Intervention: Genistein combined with FOLFOX or FOLFOX-Bevacizumab
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 13
Study: 31203498

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus Aflibercept
Number of subjects: 31
Study: 31203649

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sleep Management Control (SMC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (BBTi and SMC)
Number of subjects: 62
Study: 31204071

Group type: EXPERIMENTAL
Intervention: Sphincter-preserving surgery
Number of subjects: 203
Study: 31204145

Group type: EXPERIMENTAL
Intervention: Unloading knee brace for three months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical therapy (60-min session, three times a week for three months)
Number of subjects: 41
Study: 31204595

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral Drug-Coated Balloon
Number of subjects: 0
Study: 31204775

Group type: EXPERIMENTAL
Intervention: Overfeeding (40% above baseline energy requirements for 8 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lower-than-predicted SMR (basal EE) during follow-up
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Higher-than-predicted sedentary 24h-EE during follow-up
Number of subjects: 35
Study: 31205473

Group type: EXPERIMENTAL
Intervention: High dose antivenom
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low dose antivenom
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Preantivenom subcutaneous adrenaline (SCAd)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IV adrenaline infusion (IVAI)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 155
Study: 31205629

Group type: EXPERIMENTAL
Intervention: 1L imatinib (IM)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: 1L dasatinib (DAS)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: 1L nilotinib (NIL)
Number of subjects: 266
Study: 31205786

Group type: EXPERIMENTAL
Intervention: Urine biomarkers collected at admission and day three postarrest
Number of subjects: 195
Study: 31205944

Group type: EXPERIMENTAL
Intervention: Modified suction-assisted cartilage shaver for AO
Number of subjects: 39
Study: 31206074

Group type: EXPERIMENTAL
Intervention: 2-year camp-based immersion family treatment for obesity
Number of subjects: 90

Group type: COMPARATOR
Intervention: outpatient family-based treatment for obesity
Number of subjects: 90
Study: 31206096

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31206240

Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0
Study: 31206368

Group type: EXPERIMENTAL
Intervention: Combination of olaparib plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATM-negative tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATM (Y170) assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATM-deficiency defined by <25% tumor cell nuclei expressing ATM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of ATM levels by IHC
Number of subjects: 0
Study: 31207172

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 59
Study: 31207442

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 0
Study: 31207465

Group type: EXPERIMENTAL
Intervention: 18F-florbetaben (FBB)
Number of subjects: 25
Study: 31207561

Group type: EXPERIMENTAL
Intervention: Controlled pharmacotherapy for psychotic depression
Number of subjects: 0
Study: 31208123

Group type: EXPERIMENTAL
Intervention: Sanitary shoes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 26
Study: 31208356

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 10
Study: 31208466

Group type: EXPERIMENTAL
Intervention: DF-PAL (Dairy Farmers with PAL)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: NF-PAL (Non-farmers with PAL)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: DF-PAL
Number of subjects: 186

Group type: COMPARATOR
Intervention: NF-PAL
Number of subjects: 186
Study: 31208471

Group type: EXPERIMENTAL
Intervention: VIVIFRAIL multicomponent exercise programme
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study: 31208944

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus FCR (Fludarabine, Cyclophosphamide, Rituximab); Ibrutinib 420 mg/day for 7 days, followed by up to six 28-day cycles of FCR.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus FCR
Number of subjects: 85
Study: 31208955

Group type: EXPERIMENTAL
Intervention: Genomics-informed computational biology modeling (CBM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laboratory validation of CBM predictions
Number of subjects: 50
Study: 31209482

Group type: EXPERIMENTAL
Intervention: ICD/CRT-D replacement/upgrade
Number of subjects: 983
Study: 31210922

Group type: EXPERIMENTAL
Intervention: VEMOFIT (value-based emotion-focused educational program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control program
Number of subjects: 0
Study: 31210950

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transfer (FMT)
Number of subjects: 240
Study: 31211145

Group type: EXPERIMENTAL
Intervention: Modified method of contrast echocardiography
Number of subjects: 506

Group type: COMPARATOR
Intervention: Traditional method of contrast echocardiography
Number of subjects: 506
Study: 31211158

Group type: EXPERIMENTAL
Intervention: Live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2, single intranasal dose of 10
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study: 31211764

Group type: EXPERIMENTAL
Intervention: Pulsatile PDA with hemodynamically significant features
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Restrictive PDA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: No evidence of PDA
Number of subjects: 50
Study: 31211792

Group type: EXPERIMENTAL
Intervention: Killed bivalent (Vibrio cholerae O1 and O139) whole-cell oral cholera vaccine (SHANCHOL; Shantha Biotechnics) - 2 doses, 14 days apart
Number of subjects: 200
Study: 31212080

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) administered post-transplant
Number of subjects: 63
Study: 31212162

Group type: EXPERIMENTAL
Intervention: Lifetime breastfeeding for at least 7 months
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Older age at first live birth
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 152
Study: 31212293

Group type: COMPARATOR
Intervention: No IVH
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: IVH without obstructive hydrocephalus (IVH-w/o-EVD)
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Graeb score >2
Number of subjects: 1112
Study: 31212683

Group type: EXPERIMENTAL
Intervention: Educational text messages (3 messages weekly for 12 weeks)
Number of subjects: 79
Study: 31212833

Group type: EXPERIMENTAL
Intervention: P28GST administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P28GST treatment in Crohn's disease patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fecal microbiota transplantation from P28GST-immunized mice
Number of subjects: 0
Study: 31212934

Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 6672

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet)
Number of subjects: 6672

Group type: COMPARATOR
Intervention: Physical Activity and Mediterranean Diet (joint effect)
Number of subjects: 6672

Group type: EXPERIMENTAL
Intervention: Lean Body Mass
Number of subjects: 6672
Study: 31212997

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy
Number of subjects: 36
Study: 31213500

Group type: EXPERIMENTAL
Intervention: Binimetinib (30 mg b.i.d.) and Pexidartinib (400 mg every morning and 200 mg every evening)
Number of subjects: 2
Study: 31213778

Group type: EXPERIMENTAL
Intervention: Nurse-based intervention for improving medication adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 31213865

Group type: EXPERIMENTAL
Intervention: Roflumilast for 6 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 8
Study: 31214997

Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly for 12 weeks
Number of subjects: 218

Group type: COMPARATOR
Intervention: Daily DPP-4 inhibitor for 12 weeks
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly
Number of subjects: 218

Group type: COMPARATOR
Intervention: Daily DPP-4 inhibitor
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Trelagliptin and daily DPP-4 inhibitors
Number of subjects: 218
Study: 31215195

Group type: EXPERIMENTAL
Intervention: Fluorescent imaging agent IS-001
Number of subjects: 0
Study: 31215234

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (2-week protocol, adapted from Jon Kabat-Zinn's Mindfulness-Based Stress Reduction course)
Number of subjects: 10
Study: 31215264

Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular weight heparin and fondaparinux (Control)
Number of subjects: 0
Study: 31215448

Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane in 40% oxygen
Number of subjects: 29
Study: 31215603

Group type: EXPERIMENTAL
Intervention: Early mobilization program including progressive passive mobilization, positioning, discussion of mobilization goals, cycle ergometer, and virtual reality games.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Early mobilization protocols implemented by a multidisciplinary team.
Number of subjects: 6
Study: 31215715

Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992
Study: 31215813

Group type: EXPERIMENTAL
Intervention: Disrupted sleep
Number of subjects: 0
Study: 31215818

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31216011

Group type: EXPERIMENTAL
Intervention: Incretin-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous incretin infusions
Number of subjects: 0
Study: 31216123

Group type: EXPERIMENTAL
Intervention: Heart involvement
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Positive proteinase 3 (PR3)-ANCA
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pulmonary hemorrhage
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Urinary red blood cell casts
Number of subjects: 197
Study: 31216198

Group type: EXPERIMENTAL
Intervention: Fluorine-18-Labeled Fluciclovine PET/CT
Number of subjects: 0
Study: 31216218

Group type: EXPERIMENTAL
Intervention: Tdap vaccination (exposed cohort)
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Unvaccinated women (unexposed cohort)
Number of subjects: 1203
Study: 31216297

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser-Doppler flowmetry
Number of subjects: 0
Study: 31216376

Group type: EXPERIMENTAL
Intervention: Community-acquired respiratory viral infections (CARVs) detected in 156 patient visits (74% enterovirus/rhinovirus)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bronchiolitis obliterans syndrome incidence
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Primary endpoint met
Number of subjects: 61
Study: 31217161

Group type: EXPERIMENTAL
Intervention: Haplo-identical transplant with posttransplant cyclophosphamide (haplo)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Haplo-cord transplant supported by third-party CD34 cells (haplo-cord)
Number of subjects: 307
Study: 31217320

Group type: EXPERIMENTAL
Intervention: Lifestyle, environmental and occupational factors assessment through a standardized questionnaire and saliva sample collection.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group matched by sex, age, and district of residence.
Number of subjects: 0
Study: 31217479

Group type: EXPERIMENTAL
Intervention: TSR-011 40 mg every 8 hours (Q8h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TSR-011 320- and 480-mg Q24h doses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TSR-011 40 mg Q8h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TSR-011
Number of subjects: 14
Study: 31217818

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m² in combination with capecitabine-based radiotherapy (50 Gy/25 fractions)
Number of subjects: 52
Study: 31217992

Group type: EXPERIMENTAL
Intervention: Home-based heart failure tool (education, symptom monitoring, diuretic titration)
Number of subjects: 172
Study: 31217993

Group type: EXPERIMENTAL
Intervention: HART PAD panel (clinical variable: history of hypertension; biomarkers: midkine, kidney injury molecule-1, interleukin-23, follicle-stimulating hormone, angiopoietin-1, eotaxin-1)
Number of subjects: 354
Study: 31217997

Group type: EXPERIMENTAL
Intervention: Higher aortic stiffness (PWV >8.7 m/s)
Number of subjects: 125
Study: 31218003

Group type: EXPERIMENTAL
Intervention: Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 290

Group type: COMPARATOR
Intervention: Short Form-12 questionnaire
Number of subjects: 290
Study: 31218013

Group type: EXPERIMENTAL
Intervention: Accelerated initiation of renal replacement therapy (RRT) within 12 hours of meeting eligibility criteria
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Standard initiation of renal replacement therapy (RRT) based on clinician judgment or urgent complications
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: Accelerated initiation of RRT
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Standard initiation of RRT
Number of subjects: 2866
Study: 31218482

Group type: EXPERIMENTAL
Intervention: Thromboelastography, oxidized LDL β2-glycoprotein complex (AtherOx), oxidized-LDL, lipid profile, and urine for 11-dehydrothromboxane B
Number of subjects: 134
Study: 31218680

Group type: EXPERIMENTAL
Intervention: Home-HIT (12 weeks of virtually supervised home-based high-intensity interval training)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Home-based MICT (moderate-intensity continuous training)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laboratory-based HIT
Number of subjects: 32
Study: 31218780

Group type: EXPERIMENTAL
Intervention: Natural language processing (NLP) software application for coding clinical text documentation of overdose
Number of subjects: 0
Study: 31219045

Group type: EXPERIMENTAL
Intervention: Web-based mindfulness-based intervention (MBI)
Number of subjects: 149
Study: 31219185

Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 31219594

Group type: EXPERIMENTAL
Intervention: ICF core set and ICF-based questionnaire (Cochin Scleroderma ICF-65 questionnaire) assessing activities and participation in patients with SSc.
Number of subjects: 28
Study: 31219619

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Number of subjects: 20
Study: 31219975

Group type: EXPERIMENTAL
Intervention: Radiotherapy (R-CAR-cohort)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intensive combined chemotherapy (C-CAR-cohort)
Number of subjects: 10
Study: 31220220

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Historical control (pegylated-interferon/ribavirin)
Number of subjects: 27
Study: 31220258

Group type: EXPERIMENTAL
Intervention: Cefoxitin (loading dose followed by constant infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cefoxitin (standard dosing regimen)
Number of subjects: 8
Study: 31220276

Group type: EXPERIMENTAL
Intervention: Subcutaneous (sc) prolonged suppressive antibiotic therapy (PSAT) using ertapenem, ceftriaxone, or ceftazidime
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous (sc) PSAT
Number of subjects: 10
Study: 31220291

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 183
Study: 31220349

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (weight-based doses: 33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir
Number of subjects: 34
Study: 31220357

Group type: EXPERIMENTAL
Intervention: VCTE (vibration-controlled transient elastography)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: APRI (aspartate aminotransferase-to-platelet ratio index)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: FIB-4 index
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: APRI or FIB-4 jointly with VCTE
Number of subjects: 139
Study: 31220387

Group type: EXPERIMENTAL
Intervention: ADD-RS/ME
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: ADD-RS/aCRs
Number of subjects: 1030

Group type: COMPARATOR
Intervention: CR (per se) for ME
Number of subjects: 1030

Group type: COMPARATOR
Intervention: CR (per se) for aCRs
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: ADD-RS/ME rule-out
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: ADD-RS/aCRs rule-out
Number of subjects: 1030
Study: 31220400

Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (SRT) with pre-SRT PSA level <0.5 ng/mL
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Delayed SRT with PSA level ≥0.5 ng/mL
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Early SRT at PSA level <0.5 ng/mL
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: SRT alone in patients with PSA level ≥0.5 ng/mL and higher-risk features
Number of subjects: 555
Study: 31220413

Group type: EXPERIMENTAL
Intervention: Bilateral inferior turbinate reduction (BITR) with endoscopic sinus surgery (ESS)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) alone
Number of subjects: 571
Study: 31220623

Group type: EXPERIMENTAL
Intervention: Rapid saline infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise (semisupine ergometer at 25%, 50%, and 75% of peak VO2)
Number of subjects: 50
Study: 31220640

Group type: EXPERIMENTAL
Intervention: EUS with nCLE
Number of subjects: 144

Group type: COMPARATOR
Intervention: Measurement of CEA and cytology analysis
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Overall incidence of postprocedure acute pancreatitis
Number of subjects: 144
Study: 31220806

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0